Trial · NCT00672633
Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides
NCT00672633, Phase 2, Terminated, Boston Children's Hospital; results first posted 2013-05-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides. Trials, record NCT00672633. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00672633
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides
- NCT number
- NCT00672633
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 25 participants, actual
- Lead sponsor
- Boston Children's Hospital
- Conditions
- Hypertriglyceridemia
- Interventions
- Lovaza, Placebo
- First posted
- 2008-05-06
- Last updated
- 2013-05-29
- Results first posted
- 2013-05-29
- Limitations and caveats
- Early termination leading to small numbers of subjects analyzed
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fasting Triglycerides | 3 months | Fasting Triglycerides |
| Secondary | LDL Cholesterol | 3 months | Low Density Lipoprotein Cholesterol |
| Secondary | HDL Cholesterol | 3 months | High Density Lipoprotein Cholesterol |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Fasting Triglycerides | 3 months | Intention to Treat | mg/dL | GEOMETRIC_MEAN |
| SECONDARY | LDL Cholesterol | 3 months | mg/dL | MEAN | |
| SECONDARY | HDL Cholesterol | 3 months | Intention to Treat | mg/dL | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Fasting Triglycerides | Lovaza | 171 | Standard Error 18 | mg/dL | |
| Fasting Triglycerides | Placebo | 186 | Standard Error 20 | mg/dL | |
| LDL Cholesterol | Lovaza | 116 | Standard Error 11 | mg/dL | |
| LDL Cholesterol | Placebo | 104 | Standard Error 11 | mg/dL | |
| HDL Cholesterol | Lovaza | 35.8 | Standard Error 1.7 | mg/dL | |
| HDL Cholesterol | Placebo | 33.6 | Standard Error 1.7 | mg/dL |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Lovaza | 12 | |
| Overall Study | STARTED | Placebo | 13 | |
| Overall Study | COMPLETED | Lovaza | 12 | |
| Overall Study | COMPLETED | Placebo | 12 | |
| Overall Study | NOT COMPLETED | Lovaza | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Lovaza | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Lovaza | 0 | 12 |
| Total, other adverse events | Placebo | 0 | 12 |
| Total, serious adverse events | Lovaza | 0 | 12 |
| Total, serious adverse events | Placebo | 0 | 12 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Lovaza vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00672633
GET https://conductscience.org/api/trials/v1/NCT00672633/registered